PHILADELPHIA, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Mid-Atlantic Bio Angels (MABA) announces today that Avisi Technologies, LLC, which develops an eye implant for glaucoma, was named “Best in Show” by the audience at MABA’s 1st Pitch Life Science event held on October 16, 2018 at the Cira Centre in Philadelphia.

“We're very grateful for the opportunity to share our vision for a healthier world. 1st Pitch was a great experience - the expert judges gave us immensely valuable feedback and I look forward to incorporating what we learned into our growth strategy moving forward,” commented Rui Jing Jiang, CEO of Avisi.

Philadelphia-based Avisi Technologies, LLC (https://www.avisitech.com) is currently developing a nanoscale eye implant for glaucoma that reduces intraocular pressure, surgery time, patient discomfort and risk of blindness. The company’s product, VisiPlate, is 10,000 times thinner than competitors, mitigates risk of excessive scar tissue and post-operative problems such as double vision, and is easier to monitor by ophthalmologists after surgery.

“Rarely do we have the opportunity to see  such a well-researched and compelling science and business case from a company this early in its life cycle.  While the company is early, its invention could prove to be a significant improvement over other modalities for patients suffering glaucoma.  Rui Jing made a clear and compelling case in her presentation and I look forward to seeing this opportunity progress,” said Bernie Rudnick, MABA co-founder, and moderator at the event.

“The Avisi presentation was well-organized and very well presented.  Ms. Jiang made very clear the market need, the shortcomings of the competition and the advantages of the company's product and was fully prepared for the questions that were raised,” added Steve Goodman, MABA co-founder and partner at the law firm of Pryor Cashman LLP.  “Avisi has great potential for investment once they become a bit more mature."

About 1st Pitch Life Science
At a 1st Pitch event (http://www.1stpitchlifescience.com), early stage life sciences and healthcare companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 10-minute audience Q&A. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1st Pitch are invited to hear the panel constructively critique the company’s presentation, business model and perceived viability in the market.

About MABA
Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA’s goal is to create an environment where the depth of investors’ knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.

Contact:

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com